STOCK WATCH

BIOTECHNOLOGY firm Optibiotix Health secured a contract to provide several cholesterol and blood pressure fighting treatments to a pharmaceutical chain in New Zealand.

The firm makes products that aim to prevent disease by altering the constitution of the body. It will supply Pharmabiota with three different medicines containing a strain of bacteria called LP-LDL, which is found in the intestine and used by the food industry to fight a number of health conditions.

Shares closed flat 63.5p.